Meitav Dash Investments Ltd. raised its stake in Mediwound Ltd (NASDAQ:MDWD) by 0.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 598,508 shares of the biopharmaceutical company’s stock after acquiring an additional 3,536 shares during the period. Meitav Dash Investments Ltd. owned about 2.20% of Mediwound worth $2,993,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Sargent Investment Group LLC acquired a new position in Mediwound in the fourth quarter worth $55,000. Deutsche Bank AG boosted its stake in Mediwound by 73.5% in the fourth quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 16,840 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Mediwound by 6.5% in the first quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 2,000 shares in the last quarter. ETF Managers Group LLC boosted its stake in Mediwound by 57.4% in the fourth quarter. ETF Managers Group LLC now owns 48,085 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 17,531 shares in the last quarter. Finally, Menta Capital LLC boosted its stake in Mediwound by 200.2% in the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 29,686 shares in the last quarter. Hedge funds and other institutional investors own 30.78% of the company’s stock.
Shares of MDWD traded down $0.07 during trading hours on Friday, hitting $3.38. 16,788 shares of the stock traded hands, compared to its average volume of 220,503. The company has a quick ratio of 3.79, a current ratio of 3.99 and a debt-to-equity ratio of 0.40. Mediwound Ltd has a 1-year low of $3.00 and a 1-year high of $7.15. The stock has a market capitalization of $94.86 million, a price-to-earnings ratio of -6.90 and a beta of 0.80. The firm has a fifty day simple moving average of $3.97.
MDWD has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Mediwound from a “buy” rating to a “hold” rating in a research note on Wednesday, March 27th. Oppenheimer set a $15.00 price objective on Mediwound and gave the stock a “buy” rating in a research note on Monday, March 25th. Finally, ValuEngine lowered Mediwound from a “hold” rating to a “sell” rating in a research note on Tuesday, June 18th.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.